Market capitalization | $749.70m |
Enterprise Value | $730.70m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.12 |
P/S ratio (TTM) P/S ratio | 4.23 |
P/B ratio (TTM) P/B ratio | 3.35 |
Revenue growth (TTM) Revenue growth | -1.34% |
Revenue (TTM) Revenue | $177.28m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
7 Analysts have issued a Adaptive Biotechnologies Corp forecast:
7 Analysts have issued a Adaptive Biotechnologies Corp forecast:
Sep '24 |
+/-
%
|
||
Revenue | 177 177 |
1%
1%
|
|
Gross Profit | 90 90 |
6%
6%
|
|
EBITDA | -146 -146 |
12%
12%
|
EBIT (Operating Income) EBIT | -166 -166 |
15%
15%
|
Net Profit | -195 -195 |
0%
0%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.
Head office | United States |
CEO | Chad Robins |
Employees | 709 |
Founded | 2009 |
Website | www.adaptivebiotech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.